1215 related articles for article (PubMed ID: 34381030)
1. Mortality in individuals treated with COVID-19 convalescent plasma varies with the geographic provenance of donors.
Kunze KL; Johnson PW; van Helmond N; Senefeld JW; Petersen MM; Klassen SA; Wiggins CC; Klompas AM; Bruno KA; Mills JR; Theel ES; Buras MR; Golafshar MA; Sexton MA; Diaz Soto JC; Baker SE; Shepherd JRA; Verdun NC; Marks P; Paneth NS; Fairweather D; Wright RS; van Buskirk CM; Winters JL; Stubbs JR; Senese KA; Pletsch MC; Buchholtz ZA; Rea RF; Herasevich V; Whelan ER; Clayburn AJ; Larson KF; Ripoll JG; Andersen KJ; Lesser ER; Vogt MNP; Dennis JJ; Regimbal RJ; Bauer PR; Blair JE; Casadevall A; Carter RE; Joyner MJ
Nat Commun; 2021 Aug; 12(1):4864. PubMed ID: 34381030
[TBL] [Abstract][Full Text] [Related]
2. Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19.
Joyner MJ; Carter RE; Senefeld JW; Klassen SA; Mills JR; Johnson PW; Theel ES; Wiggins CC; Bruno KA; Klompas AM; Lesser ER; Kunze KL; Sexton MA; Diaz Soto JC; Baker SE; Shepherd JRA; van Helmond N; Verdun NC; Marks P; van Buskirk CM; Winters JL; Stubbs JR; Rea RF; Hodge DO; Herasevich V; Whelan ER; Clayburn AJ; Larson KF; Ripoll JG; Andersen KJ; Buras MR; Vogt MNP; Dennis JJ; Regimbal RJ; Bauer PR; Blair JE; Paneth NS; Fairweather D; Wright RS; Casadevall A
N Engl J Med; 2021 Mar; 384(11):1015-1027. PubMed ID: 33523609
[TBL] [Abstract][Full Text] [Related]
3. Convalescent Plasma for Preventing Critical Illness in COVID-19: a Phase 2 Trial and Immune Profile.
Sturek JM; Thomas TA; Gorham JD; Sheppard CA; Raymond AH; Petros De Guex K; Harrington WB; Barros AJ; Madden GR; Alkabab YM; Lu DY; Liu Q; Poulter MD; Mathers AJ; Thakur A; Schalk DL; Kubicka EM; Lum LG; Heysell SK
Microbiol Spectr; 2022 Feb; 10(1):e0256021. PubMed ID: 35196802
[TBL] [Abstract][Full Text] [Related]
4. Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: A national registry study.
Senefeld JW; Johnson PW; Kunze KL; Bloch EM; van Helmond N; Golafshar MA; Klassen SA; Klompas AM; Sexton MA; Diaz Soto JC; Grossman BJ; Tobian AAR; Goel R; Wiggins CC; Bruno KA; van Buskirk CM; Stubbs JR; Winters JL; Casadevall A; Paneth NS; Shaz BH; Petersen MM; Sachais BS; Buras MR; Wieczorek MA; Russoniello B; Dumont LJ; Baker SE; Vassallo RR; Shepherd JRA; Young PP; Verdun NC; Marks P; Haley NR; Rea RF; Katz L; Herasevich V; Waxman DA; Whelan ER; Bergman A; Clayburn AJ; Grabowski MK; Larson KF; Ripoll JG; Andersen KJ; Vogt MNP; Dennis JJ; Regimbal RJ; Bauer PR; Blair JE; Buchholtz ZA; Pletsch MC; Wright K; Greenshields JT; Joyner MJ; Wright RS; Carter RE; Fairweather D
PLoS Med; 2021 Dec; 18(12):e1003872. PubMed ID: 34928960
[TBL] [Abstract][Full Text] [Related]
5. Determination of neutralising anti-SARS-CoV-2 antibody half-life in COVID-19 convalescent donors.
Barnes TW; Schulte-Pelkum J; Steller L; Filchtinski D; Jenness R; Williams MR; Kober C; Manni S; Hauser T; Hahn A; Kalina U; Simon TL; Schuetz P; Roth NJ
Clin Immunol; 2021 Nov; 232():108871. PubMed ID: 34619377
[TBL] [Abstract][Full Text] [Related]
6. Early Convalescent Plasma for High-Risk Outpatients with Covid-19.
Korley FK; Durkalski-Mauldin V; Yeatts SD; Schulman K; Davenport RD; Dumont LJ; El Kassar N; Foster LD; Hah JM; Jaiswal S; Kaplan A; Lowell E; McDyer JF; Quinn J; Triulzi DJ; Van Huysen C; Stevenson VLW; Yadav K; Jones CW; Kea B; Burnett A; Reynolds JC; Greineder CF; Haas NL; Beiser DG; Silbergleit R; Barsan W; Callaway CW;
N Engl J Med; 2021 Nov; 385(21):1951-1960. PubMed ID: 34407339
[TBL] [Abstract][Full Text] [Related]
7. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.
Shen C; Wang Z; Zhao F; Yang Y; Li J; Yuan J; Wang F; Li D; Yang M; Xing L; Wei J; Xiao H; Yang Y; Qu J; Qing L; Chen L; Xu Z; Peng L; Li Y; Zheng H; Chen F; Huang K; Jiang Y; Liu D; Zhang Z; Liu Y; Liu L
JAMA; 2020 Apr; 323(16):1582-1589. PubMed ID: 32219428
[TBL] [Abstract][Full Text] [Related]
8. Case Report: Serial Cases: Prolongation of High Immunoglobulin G Level in Repetitive COVID-19 Convalescence Plasma Donor in Saiful Anwar Hospital Malang, Indonesia.
Nurarifah N; Brahmantyo HP; Wardhani SO; Hermanto DH; Arsana PM
Front Immunol; 2021; 12():633323. PubMed ID: 34790190
[TBL] [Abstract][Full Text] [Related]
9. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
[TBL] [Abstract][Full Text] [Related]
10. Case Series: Convalescent Plasma Therapy for Patients with COVID-19 and Primary Antibody Deficiency.
Lang-Meli J; Fuchs J; Mathé P; Ho HE; Kern L; Jaki L; Rusignuolo G; Mertins S; Somogyi V; Neumann-Haefelin C; Trinkmann F; Müller M; Thimme R; Umhau M; Quinti I; Wagner D; Panning M; Cunningham-Rundles C; Laubner K; Warnatz K
J Clin Immunol; 2022 Feb; 42(2):253-265. PubMed ID: 34893946
[TBL] [Abstract][Full Text] [Related]
11. Early safety indicators of COVID-19 convalescent plasma in 5000 patients.
Joyner MJ; Wright RS; Fairweather D; Senefeld JW; Bruno KA; Klassen SA; Carter RE; Klompas AM; Wiggins CC; Shepherd JR; Rea RF; Whelan ER; Clayburn AJ; Spiegel MR; Johnson PW; Lesser ER; Baker SE; Larson KF; Ripoll JG; Andersen KJ; Hodge DO; Kunze KL; Buras MR; Vogt MN; Herasevich V; Dennis JJ; Regimbal RJ; Bauer PR; Blair JE; Van Buskirk CM; Winters JL; Stubbs JR; Paneth NS; Verdun NC; Marks P; Casadevall A
J Clin Invest; 2020 Sep; 130(9):4791-4797. PubMed ID: 32525844
[TBL] [Abstract][Full Text] [Related]
12. Locally harvested Covid-19 convalescent plasma could probably help combat the geographically determined SARS-CoV-2 viral variants.
Raturi M; Kusum A; Kala M; Mittal G; Sharma A; Bansal N
Transfus Clin Biol; 2021 Aug; 28(3):300-302. PubMed ID: 33971318
[TBL] [Abstract][Full Text] [Related]
13. Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial.
Soto A; Krapp F; Vargas A; Cabrejos L; Argumanis E; García PL; Altamirano K; Montes M; Chacón-Uscamaita PR; García PJ
Trials; 2021 May; 22(1):342. PubMed ID: 34001174
[TBL] [Abstract][Full Text] [Related]
14. Clinical predictors of donor antibody titre and correlation with recipient antibody response in a COVID-19 convalescent plasma clinical trial.
Madariaga MLL; Guthmiller JJ; Schrantz S; Jansen MO; Christensen C; Kumar M; Prochaska M; Wool G; Durkin-Celauro A; Oh WH; Trockman L; Vigneswaran J; Keskey R; Shaw DG; Dugan H; Zheng NY; Cobb M; Utset H; Wang J; Stovicek O; Bethel C; Matushek S; Giurcanu M; Beavis KG; di Sabato D; Meltzer D; Ferguson MK; Kress JP; Shanmugarajah K; Matthews JB; Fung JF; Wilson PC; Alverdy JC; Donington JS
J Intern Med; 2021 Apr; 289(4):559-573. PubMed ID: 33034095
[TBL] [Abstract][Full Text] [Related]
15. Detection of SARS-CoV-2-independent immunoregulatory activity of COVID-19 convalescent plasma.
Brox R; Achenbach S; Hackstein H
Transfusion; 2021 Nov; 61(11):3087-3093. PubMed ID: 34546583
[TBL] [Abstract][Full Text] [Related]
16. Convalescent plasma therapy for the treatment of patients with COVID-19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels.
Harvala H; Robb ML; Watkins N; Ijaz S; Dicks S; Patel M; Supasa P; Wanwisa D; Liu C; Mongkolsapaya J; Bown A; Bailey D; Vipond R; Grayson N; Temperton N; Gupta S; Ploeg RJ; Bolton J; Fyfe A; Gopal R; Simmonds P; Screaton G; Thompson C; Brooks T; Zambon M; Miflin G; Roberts DJ
Transfus Med; 2021 Jun; 31(3):167-175. PubMed ID: 33333627
[TBL] [Abstract][Full Text] [Related]
17. Administration of high titer convalescent anti-SARS-CoV-2 plasma: From donor selection to monitoring recipient outcomes.
Mendoza RP; Fyke W; Daniel D; Gabutan E; Das B; Bajaj H; Easy M; Vasileva A; Colbourn R; Alawad M; Dehghani A; Lin B; Emechebe D; Patel P; Jabbar A; Nikolov DB; Giovaniello D; Kang S; Tatem L; Bromberg K; Augenbraun M; Premsrirut P; Libien J; Norin AJ
Hum Immunol; 2021 Apr; 82(4):255-263. PubMed ID: 33640208
[TBL] [Abstract][Full Text] [Related]
18. Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks.
Wooding DJ; Bach H
Clin Microbiol Infect; 2020 Oct; 26(10):1436-1446. PubMed ID: 32791241
[TBL] [Abstract][Full Text] [Related]
19. Impact of Convalescent Plasma Therapy on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Profile in Coronavirus Disease 2019 (COVID-19) Patients.
Tang J; Grubbs G; Lee Y; Golding H; Khurana S
Clin Infect Dis; 2022 Jan; 74(2):327-334. PubMed ID: 33861337
[TBL] [Abstract][Full Text] [Related]
20. Regulatory challenges of convalescent plasma collection during the evolving stages of COVID-19 pandemic in the United States.
Hassan S; West KA; Conry-Cantilena K; De Giorgi V
Transfusion; 2022 Feb; 62(2):483-492. PubMed ID: 34778974
[No Abstract] [Full Text] [Related]
[Next] [New Search]
